Muscles need dystrophin in order to regenerate. Persons suffering from Duchenne muscular dystrophy lack this essential muscular protein due to mutations in the gene which is responsible for producing dystrophin. As a result, their existing muscle cells deteriorate over time and are gradually replaced by connective and fatty tissue; muscle strength weakens during the course of the disease. The first symptoms usually appear around the age of five. Children with the disease begin to have difficulties with movements they previously completed with ease, for example climbing stairs or getting up from the floor. At approximately the age of twelve, they are no longer able to walk, later losing movement in their arms and hands. Due to concomitant respiratory and cardiac failure, the majority of patients does not reach the age of 40. DMD affects mainly boys, since the responsible mutations are located in the dystrophin gene on the X chromosome.
Gene scissors remove defective gene sequence
An interdisciplinary Munich research team led by scientists from TUM has for the first time succeeded in correcting the mutated dystrophin gene in living pigs. In order to cut the defective gene sequence from the DNA of the animals’ muscle and heart cells, the researchers modified the Crispr-Cas9 gene scissors. “These gene scissors are highly efficient and specifically corrected the dystrophin gene,” says Prof. Wolfgang Wurst, developmental geneticist at TUM and the German Research Center for Environmental Health. It became then again possible to viably read the gene which had been unreadable because of the genetic defect, thus allowing for a successful protein biosynthesis. Now the shorter but stably formed dystrophin protein was able to improve muscle function. The animals treated were less susceptible to cardiac arrhythmia and had an increased life expectancy compared to animals with the disease that did not receive the therapy.
A permanent therapy
“Muscle and heart cells are long-lived cell structures. One half of all myocardial cells remain functional from birth throughout the entire lifecycle of a human being,” says Prof. Christian Kupatt, cardiologist at university hospital TUM Klinikum rechts der Isar. “The genome of a cell is used for protein biosynthesis as long as the cell is alive, and once a cell has been affected by the therapy, it remains corrected. So if we change the genome of a myocardial cell, the correction is a long-term success, in contrast to the results of previous methods.”
Therapeutic success with clinically relevant model
The gene sequence responsible for the dystrophin protein has already been successfully corrected in the past, however in mice and other animal models. “Our results are very promising, since for the first time, we have now been able to demonstrate therapeutic success in a clinically relevant large animal model,” says Prof. Maggie Walter, neurologist at the LMU university hospital. In terms of important biochemical, clinical and pathological changes, the pig model mirrors Duchenne muscular dystrophy in humans. “Since the disease proceeds faster in our pig model, we were able to verify the efficacy of the therapeutic approaches within a manageable period of time,” says Prof. Eckhard Wolf, LMU specialist in veterinary medicine.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Duchenne muscular dystrophy
- Sarepta Addressing Gene Therapy Issue With Two Acquisitionson June 23, 2020 at 1:05 pm
Sarepta has made several deals in the past several years that have made gene therapy a key part of its business, which had been dominated by drugs for muscular dystrophy. One of those pacts, with ...
- Selecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene Therapyon June 23, 2020 at 12:19 pm
Partnership strategy for ImmTOR platform continues to pay off with Sarepta deal immediately following $100 million upfront Sobi deal. Sarepta is a big time play ...
- Duchenne Muscular Dystrophy Treatment Market | Global Industry Analysis By Size, Growth Rate and Trends With Forecast 2020 To 2026on June 23, 2020 at 12:46 am
Duchenne Muscular Dystrophy Treatment Market- 2020 Global Industry Trends, Size, Share Analysis Report. According to ...
- UK’s MHRA renews EAMS Scientific Opinion for Santhera’s Idebenone in Duchenne Muscular Dystrophyon June 22, 2020 at 10:13 pm
Stock quotes by finanzen.net Pratteln, Switzerland, June 23, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed ...
- Sarepta closes deal for Selecta platform for use in muscular dystrophieson June 18, 2020 at 1:46 pm
(SRPT +1.9%) inks an agreement with Selecta Biosciences (SELB +17.3%) for an option to license the latter's ImmTOR platform for use in Duchenne muscular dystrophy (DMD) an ...
Go deeper with Google Headlines on:
Duchenne muscular dystrophy
Go deeper with Bing News on:
Gene correction therapy
- Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapieson June 15, 2020 at 7:24 am
The companies will explore the use of MGTA-117, which is currently in preclinical IND-enabling studies as a conditioning regimen for patients receiving gene therapy designed to be less toxic than the ...
- Stem Cell Therapy for Cystic Fibrosis: Current Status and Future Prospectson June 11, 2020 at 5:00 pm
Although cystic fibrosis (CF), an autosomal recessive disease caused by mutations in the gene encoding ... cell-based therapy of CF-injured lungs should achieve a permanent correction of the ...
- An overview of development in gene therapeutics in Chinaon June 11, 2020 at 8:32 am
After setbacks related to serious adverse events 20 years ago, gene therapy is now coming back to the central stage worldwide. In the past few years, gene therapy has shown astonishing efficacy ...
- Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiencyon June 10, 2020 at 5:00 pm
We reviewed long-term outcomes after gene therapy in nine patients with X-linked severe combined immunodeficiency ... B cells were not detected. Correction of the immunodeficiency improved ...
- An Update In Layleen Polanco’s Case Demands An Immediate Need For Cash Bail Reformon June 8, 2020 at 4:03 pm
Although the Department of Investigation probe did not uncover any criminality in the way Polanco was treated, it did find that corrections officers had failed to check in on Polanco in her cell ...